Belantamab Mafodotin
Corneal Disorder
Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Hellenic Society of Hematology
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05573802CT.gov A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05833737CT.gov Corneal Findings in Patients Treated With Belantamab Mafodotin | — | Terminated | — | — | — |
NCT05581875CT.gov A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | — | Not Yet Recruiting | — | — | — |
NCT05280275CT.gov A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Corneal Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Belantamab Mafodotin (this asset) | Hellenic Society of Hematology | P1/2 | CC · 47 |
| Pomalidomide | Hellenic Society of Hematology | P1/2 | CC |
| Lenalidomide | Hellenic Society of Hematology | P1/2 | CC |
| Dexasone | Hellenic Society of Hematology | P1/2 | CC |
| Daratumumab | Hellenic Society of Hematology | P1/2 | CC |
| Nirogacestat | Hellenic Society of Hematology | P1/2 | CC |
| Cenegermin-Bkbj | Tufts Medical Center | P1 | CC |
| Human Cord Blood Plasma | Singapore Eye Research Institute | N/A | D |
Other indications for Belantamab Mafodotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P3 | B · 58 |
| Plasma Cell Neoplasm | — | P1/2 | CCC · 48 |
| Hematologic Disorder | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Belantamab Mafodotin in Corneal Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/belantamab-mafodotin-corneal-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →